Kiniksa Pharmaceuticals International (KNSA) EBIAT: 2021-2025
Historic EBIAT for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $18.4 million.
- Kiniksa Pharmaceuticals International's EBIAT rose 245.24% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.9 million, marking a year-over-year increase of 496.10%. This contributed to the annual value of -$43.2 million for FY2024, which is 406.68% down from last year.
- Kiniksa Pharmaceuticals International's EBIAT amounted to $18.4 million in Q3 2025, which was up 3.38% from $17.8 million recorded in Q2 2025.
- In the past 5 years, Kiniksa Pharmaceuticals International's EBIAT ranged from a high of $224.1 million in Q3 2022 and a low of -$49.5 million during Q1 2021.
- Moreover, its 3-year median value for EBIAT was -$3.9 million (2024), whereas its average is $1.4 million.
- In the last 5 years, Kiniksa Pharmaceuticals International's EBIAT skyrocketed by 833.67% in 2022 and then tumbled by 135.22% in 2024.
- Kiniksa Pharmaceuticals International's EBIAT (Quarterly) stood at -$36.3 million in 2021, then spiked by 112.28% to $4.5 million in 2022, then spiked by 465.73% to $25.2 million in 2023, then slumped by 135.22% to -$8.9 million in 2024, then spiked by 245.24% to $18.4 million in 2025.
- Its EBIAT stands at $18.4 million for Q3 2025, versus $17.8 million for Q2 2025 and $8.5 million for Q1 2025.